120165-53-9

Upstream product

• 69477-72-1 N-(4-hydroxy-2,3,5-trimethylphenyl)acetamide 
• 857554-09-7 acetic acid-(4-methoxy-2,3,5-trimethyl-anilide) 
• 142279-85-4 2-methoxy-1,3,4-trimethyl-5-nitrobenzene 
• 17959-06-7 4-hydroxy-2,3,5-trimethylaniline 

Downstream Products

• 860192-03-6 6-methoxy-3-(4-methoxy-2,3,5-trimethyl-phenyl)-5,7,8-trimethyl-1,2,3,4-tetrahydro-quinazoline 
• 891188-48-0 ethyl 1-((4-methoxy-2,3,5-trimethylphenylamino)methyl)-cyclobutanecarboxylate 
• 120165-52-8 2-amino-6-methoxy-4,5,7-trimethylbenzothiazole 
• 860192-75-2 6-methoxy-3-(4-methoxy-2,3,5-trimethyl-phenyl)-5,7,8-trimethyl-3,4-dihydro-quinazoline 

Relevant academic research and scientific papers

Spiro derivatives as lipoxygenase inhibitors

The present invention is concerned with certain novel spiro substituted heterocylic ring derivatives. These compounds may be useful in the manufacture of pharmaceutical compositions for treating disorders mediated by lipoxygenases. They may also be useful

Tetrahydroindenoindole compounds useful in the treatment of conditions associated with free radical formation

The invention concerns compounds and their enantiomers of the formula IA or IB STR1 and pharmaceutically acceptable salts thereof wherein each of R1, R2, R3, R4, R6, R7, R8, R9, R10, R11 and R12 is independently selected from hydrogen or an alkyl group containing 1-6 carbon atoms and R5 is an alkoxy group containing 1-6 carbon atoms. The invention further concerns pharmaceutical compositions comprising the active compounds and methods employing the compounds for the treatment of conditions associated with free radical formation.

Indenoindole compounds

Cis-fused compounds of the formula I wherein R is methoxy or ethoxy, when R is methoxy, R1 is methyl and R2 and R3 are both hydrogen or both methyl, and when R is ethoxy, R1 is hydrogen and R2 and R3 are both methyl, and enantiomers and salts thereof are